Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study.
van Baardwijk A, Bosmans G, Boersma L, Wanders S, Dekker A, Dingemans AM, Bootsma G, Geraedts W, Pitz C, Simons J, Lambin P, De Ruysscher D. van Baardwijk A, et al. Among authors: geraedts w. Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1394-401. doi: 10.1016/j.ijrobp.2007.11.070. Epub 2008 Feb 6. Int J Radiat Oncol Biol Phys. 2008. PMID: 18258380
Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy.
Dehing-Oberije C, De Ruysscher D, van der Weide H, Hochstenbag M, Bootsma G, Geraedts W, Pitz C, Simons J, Teule J, Rahmy A, Thimister P, Steck H, Lambin P. Dehing-Oberije C, et al. Among authors: geraedts w. Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1039-44. doi: 10.1016/j.ijrobp.2007.07.2323. Epub 2007 Sep 24. Int J Radiat Oncol Biol Phys. 2008. PMID: 17889446
HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer.
De Ruysscher D, Wanders R, van Haren E, Hochstenbag M, Geraedts W, Pitz C, Simons J, Boersma L, Verschueren T, Minken A, Bentzen SM, Lambin P. De Ruysscher D, et al. Among authors: geraedts w. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):132-8. doi: 10.1016/j.ijrobp.2007.09.048. Epub 2007 Nov 26. Int J Radiat Oncol Biol Phys. 2008. PMID: 18037581 Clinical Trial.
Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer.
De Ruysscher D, Dehing C, Yu S, Wanders R, Ollers M, Dingemans AM, Bootsma G, Hochstenbag M, Geraedts W, Pitz C, Simons J, Boersma L, Borger J, Dekker A, Lambin P. De Ruysscher D, et al. Among authors: geraedts w. Radiother Oncol. 2009 Jun;91(3):353-9. doi: 10.1016/j.radonc.2008.10.006. Epub 2008 Nov 13. Radiother Oncol. 2009. PMID: 19012981
Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study.
van Loon J, Grutters J, Wanders R, Boersma L, Oellers M, Dingemans AM, Bootsma G, Geraedts W, Pitz C, Simons J, Fatah SA, Snoep G, Hochstenbag M, Lambin P, De Ruysscher D. van Loon J, et al. Among authors: geraedts w. Eur J Cancer. 2009 Mar;45(4):588-95. doi: 10.1016/j.ejca.2008.10.017. Epub 2008 Dec 4. Eur J Cancer. 2009. PMID: 19046631
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.
Aerts HJ, van Baardwijk AA, Petit SF, Offermann C, Loon Jv, Houben R, Dingemans AM, Wanders R, Boersma L, Borger J, Bootsma G, Geraedts W, Pitz C, Simons J, Wouters BG, Oellers M, Lambin P, Bosmans G, Dekker AL, De Ruysscher D. Aerts HJ, et al. Among authors: geraedts w. Radiother Oncol. 2009 Jun;91(3):386-92. doi: 10.1016/j.radonc.2009.03.006. Epub 2009 Mar 28. Radiother Oncol. 2009. PMID: 19329207 Free PMC article.
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study.
van Loon J, De Ruysscher D, Wanders R, Boersma L, Simons J, Oellers M, Dingemans AM, Hochstenbag M, Bootsma G, Geraedts W, Pitz C, Teule J, Rhami A, Thimister W, Snoep G, Dehing-Oberije C, Lambin P. van Loon J, et al. Among authors: geraedts w. Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):329-36. doi: 10.1016/j.ijrobp.2009.04.075. Epub 2009 Sep 24. Int J Radiat Oncol Biol Phys. 2010. PMID: 19782478
18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
van Loon J, Grutters JP, Wanders R, Boersma L, Dingemans AM, Bootsma G, Geraedts W, Pitz C, Simons J, Brans B, Snoep G, Hochstenbag M, Lambin P, De Ruysscher D. van Loon J, et al. Among authors: geraedts w. Eur J Cancer. 2010 Jan;46(1):110-9. doi: 10.1016/j.ejca.2009.10.028. Eur J Cancer. 2010. PMID: 19944595
Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer.
van Baardwijk A, Wanders S, Boersma L, Borger J, Ollers M, Dingemans AM, Bootsma G, Geraedts W, Pitz C, Lunde R, Lambin P, De Ruysscher D. van Baardwijk A, et al. Among authors: geraedts w. J Clin Oncol. 2010 Mar 10;28(8):1380-6. doi: 10.1200/JCO.2009.24.7221. Epub 2010 Feb 8. J Clin Oncol. 2010. PMID: 20142596
Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study.
Wanders R, Steevens J, Botterweck A, Dingemans AM, Reymen B, Baardwijk Av, Borger J, Bootsma G, Pitz C, Lunde R, Geraedts W, Lambin P, De Ruysscher D. Wanders R, et al. Among authors: geraedts w. Eur J Cancer. 2011 Dec;47(18):2691-7. doi: 10.1016/j.ejca.2011.06.023. Epub 2011 Jul 4. Eur J Cancer. 2011. PMID: 21733675 Free article.
27 results